Search - tctmd.com

Displaying 721 - 740 of 1127

Sort: Relevancy | Date

News Conference News SCAI 2016

Gender and TAVR: Studies Highlight Different Outcomes Between Men and Women

L.A. McKeown

May 11, 2016

News Daily News

Potential Benefits of Drug-Coated Balloons for Infrapopliteal Disease Remain Uncertain

Todd Neale

April 28, 2016

News Daily News

Everolimus Stent Better Than Paclitaxel Stent in Diabetic Patients, Even Those Requiring Insulin: TUXEDO Analysis

Michael O'Riordan

April 25, 2016

News Daily News

Dietary Habits May Aid Secondary Prevention in Patients With Stable CHD

Caitlin E. Cox

April 25, 2016

News Daily News

A-fib Post-TAVR Associated With Increased Risk of Mortality, Bleeding

Michael O'Riordan

April 18, 2016

News Daily News

Another CV Outcomes Trial Testing Weight-Loss Drug Contrave Terminated Early

Michael O'Riordan

April 14, 2016

News Conference News ACC 2016

Self-Expanding Transcatheter Valve Maintains Advantage Over Surgery at 3 Years in High-Risk Elderly Patients

L.A. McKeown

April 04, 2016

News Industry News

LivaNova PLC Announces the First Patient Enrolled in the PERSIST-AVR Trial

April 04, 2016

News Conference News ACC 2016

When Chosen Wisely, 90-Year-Olds Do Well After TAVR

Caitlin E. Cox

April 02, 2016

News Daily News

Same-Day Discharge After PCI Is Safe, With Benefits for Patients and Hospitals: Review

Todd Neale

April 01, 2016

News Daily News

IVUS Guidance Beneficial for Diffuse Lesions in the Modern Stent Era

Todd Neale

March 22, 2016

News Daily News

备受争议的 LIGHT 试验现已发表，但未能证实 Contrave 的心血管风险

Michael O'Riordan

March 08, 2016

News Daily News

Newer-Generation DES With Abbreviated DAPT Bests BMS in Patients at High Risk for Bleeding

L.A. McKeown

March 08, 2016

News Daily News

Controversial LIGHT Trial Now Published but Fails to Illuminate CV Risks of Contrave

Michael O'Riordan

March 08, 2016

News Industry News

Victoza® Significantly Reduced the Risk of Major Adverse Cardiovascular Events in the LEADER Trial

March 06, 2016

News Daily News

Postpone Noncardiac Surgery at Least a Year in Patients with Stents of Any Type: Registry Analysis

L.A. McKeown

March 01, 2016

News Industry News

Micell Technologies Highlights Data From Published Propensity Analysis of MiStent SES® and Market Standard Xience V® Coronary Stent

February 24, 2016

News Daily News

Covered Stents Show Promise in Patients With Aortic Coarctation: COAST II

L.A. McKeown

February 21, 2016

News Daily News

Diabetes More Influential Than CAD Complexity in DES-Treated Patients

L.A. McKeown

February 03, 2016

News Daily News

Cath-Lab Complications: New Analysis Pinpoints Rate and Risks of Intraprocedural Thrombotic Events in ACS

Shelley Wood

January 21, 2016

Advertisement

Gender and TAVR: Studies Highlight Different Outcomes Between Men and Women

Potential Benefits of Drug-Coated Balloons for Infrapopliteal Disease Remain Uncertain

Everolimus Stent Better Than Paclitaxel Stent in Diabetic Patients, Even Those Requiring Insulin: TUXEDO Analysis

Dietary Habits May Aid Secondary Prevention in Patients With Stable CHD

A-fib Post-TAVR Associated With Increased Risk of Mortality, Bleeding

Another CV Outcomes Trial Testing Weight-Loss Drug Contrave Terminated Early

Self-Expanding Transcatheter Valve Maintains Advantage Over Surgery at 3 Years in High-Risk Elderly Patients

LivaNova PLC Announces the First Patient Enrolled in the PERSIST-AVR Trial

When Chosen Wisely, 90-Year-Olds Do Well After TAVR

Same-Day Discharge After PCI Is Safe, With Benefits for Patients and Hospitals: Review

IVUS Guidance Beneficial for Diffuse Lesions in the Modern Stent Era

备受争议的 LIGHT 试验现已发表，但未能证实 Contrave 的心血管风险

Newer-Generation DES With Abbreviated DAPT Bests BMS in Patients at High Risk for Bleeding

Controversial LIGHT Trial Now Published but Fails to Illuminate CV Risks of Contrave

Victoza® Significantly Reduced the Risk of Major Adverse Cardiovascular Events in the LEADER Trial

Postpone Noncardiac Surgery at Least a Year in Patients with Stents of Any Type: Registry Analysis

Micell Technologies Highlights Data From Published Propensity Analysis of MiStent SES® and Market Standard Xience V® Coronary Stent

Covered Stents Show Promise in Patients With Aortic Coarctation: COAST II

Diabetes More Influential Than CAD Complexity in DES-Treated Patients

Cath-Lab Complications: New Analysis Pinpoints Rate and Risks of Intraprocedural Thrombotic Events in ACS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content